Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.61 |
| ▸ | CDK2 | P24941 | 20/20 | 0.61 |
| ▸ | KDR | P35968 | 16/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985995 | 0.90 | CDK1 (0.66) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3983693 | 0.90 | CDK1 (0.61) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3983541 | 0.88 | CDK1 (0.68) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3983826 | 0.87 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3983687 | 0.86 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3982768 | 0.86 | CDK1 (0.58) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3986947 | 0.86 | CDK1 (0.60) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3979909 | 0.81 | CDK1 (0.56) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3984442 | 0.81 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3983313 | 0.79 | CDK1 (0.61) | CDK1CDK2KDRCCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059511-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | CDK1 6/4885CDK2 4/4885KDR 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.